EVE Health Signs Men's Sexual Health Pharmacy Deal

EVE Health Group has agreed to commercialise men's sexual health formulations in Australia through Optimal Pharmacy Plus Stafford.

Updated on Nov. 10, 2026 in Sex Life

Plain amber glass vessels and a steel mortar rest on a pale timber bench in a bright, clean compounding room.
EVE Health Group signed a binding agreement with Optimal Pharmacy Plus Stafford to commercialise men's sexual health formulations in Australia. AI Illustration. Upload story photo >

EVE Health Group, listed on the ASX under the ticker EVE, has signed a binding agreement with Optimal Pharmacy Plus Stafford to commercialise men's sexual health formulations in Australia. The initial range is designed to address erectile dysfunction and premature ejaculation.

Why it matters

The arrangement lets EVE reach the Australian market without building its own compounding operation, a capital-light route to market. For Australian men seeking treatment for these conditions, it creates a new pathway to compounded medicines dispensed against valid prescriptions.

The agreement splits distributable profit 75% to EVE Health Group and 25% to Optimal Pharmacy Plus Stafford, after specified direct compounding and delivery costs. No minimum purchase volumes or guaranteed revenues have been set, and launch timing remains uncertain.

The players

EVE Health Group

An ASX-listed company that develops patent-pending men's sexual health formulations and is pursuing a capital-light route to market.

Optimal Pharmacy Plus Stafford

A pharmacy that will compound, prepare and deliver the products to patients under the agreement.

The details

Optimal will source ingredients, prepare medicines compounded for individual patients against valid prescriptions, and deliver them to patients. EVE provides its patent-pending formulation technology and commercial support, and retains full ownership of its intellectual property. Independent clinicians remain responsible for prescribing decisions.

Timeline

  1. The agreement was published on 10 November 2026.

  2. Supply must commence within three months of signing, or EVE may terminate.

  3. The initial term runs for two years from first supply.

  4. The agreement then renews in successive 12-month periods unless 90 days' notice is given.

Market Landscape

The agreement reflects a broader pattern in which listed health companies partner with community pharmacies to bring compounded medicines to market without owning manufacturing. It places EVE's formulation platform inside the existing Australian compounding network rather than building a separate distribution channel.

Australian men with erectile dysfunction or premature ejaculation may eventually access these compounded medicines through a pharmacy prescription. Launch timing has not been set, so no immediate change to daily options is confirmed.

The takeaway

Men considering treatment for erectile dysfunction or premature ejaculation should discuss options with an independent clinician, who remains responsible for prescribing decisions. Availability of these compounded products will depend on when supply actually begins.

Further reading

For more on intimate wellbeing topics, explore the Sex Life section.

Source note: This article includes information reported by Small Caps.